HEPATIQ for quantitative liver function.
HEPATIQ is the first automated software to provide quantitative liver function (PHM) using nuclear medicine. Other tests on the market estimate liver fibrosis (or scarring) and do not quantitate liver function. HEPATIQ also provides liver and spleen volumes (fLV and fSV) which aid in differential diagnosis.
Scarring damage can be mitigated by increased blood flow and generation of new functioning lobules. Patient outcomes are determined by the residual liver function, not the extent of scarring. This was shown in the HALT-C trial which concluded that quantitative liver function “… may be superior to histological staging by liver biopsy in identifying both high- and low-risk groups and may be more accurate than staging fibrosis in predicting clinical outcomes”.
Baseline PHM was significantly lower and fSV significantly larger in HALT-C patients who experienced outcomes including variceal bleeding, ascites, hepatic encephalopathy, and liver-related death. This trial also showed that Ishak fibrosis stage dropped from significance in the prediction of clinical outcomes in models that included PHM or fSV.
HEPATIQ has been cleared by the FDA. More information at www.hepatiq.com.
Brands: HEPATIQ provides quantitative liver function (PHM), liver and spleen volumes (fLV/fSV) which aid in the diagnosis, staging and management of liver disease. HEPATIQ is FDA cleared. www.hepatiq.com.